Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Galena Biopharma Inc    

GALENA BIOPHARMA INC
Mes dernières consult.
Most popular
  Report  
 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Financials (USD)
Sales 2018 -
EBIT 2018 -20,6 M
Net income 2018 -23,5 M
Debt 2018 -
Yield 2018 -
Sales 2019 -
EBIT 2019 -25,4 M
Net income 2019 -26,9 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 0
Capi. / Sales2019 0
Capitalization 32,9 M
More Financials
Company
SELLAS Life Sciences Group, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the development and commercialization of novel cancer immunotherapeutic for a broad range of indications.Its product galinpepimut-S, or GPS, is an immunotherapeutic agent licensed from Memorial... 
Sector
Pharmaceuticals
Calendar
-
More about the company
Latest news on GALENA BIOPHARMA INC
06/13SELLAS LIFE SCIENCES GROUP, INC. : Change in Directors or Principal Officers, Su..
AQ
06/04SELLAS Life Sciences Presents Interim Phase 1 Clinical Data of Galinpepimut-S..
GL
06/01SELLAS LIFE SCIENCES GROUP, INC. : Entry into a Material Definitive Agreement, C..
AQ
06/01SELLAS Life Sciences Provides Clinical Update on Phase 2b NeuVax™ (neli..
GL
05/24SELLAS LIFE SCIENCES GROUP, INC. : Entry into a Material Definitive Agreement (f..
AQ
05/17SELLAS Life Sciences to Present Phase 1/2 Clinical Data of Galinpepimut-S (GP..
GL
05/15SELLAS LIFE SCIENCES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITI..
AQ
05/09SELLAS Life Sciences Receives FDA Orphan Drug Designation for Galinpepimut-S ..
GL
05/02SELLAS LIFE SCIENCES GROUP, INC. : Entry into a Material Definitive Agreement, U..
AQ
05/02SELLAS LIFE SCIENCES : Completes Second Tranche of $10,700,000 Private Placement
AQ
More news
Sector news : Pharmaceuticals - NEC
06/19High Times refreshes IPO plans as cannabis companies build buzz on Wall Stree..
RE
06/19MERCK : to Distribute HistoCyte Laboratories Products
DJ
06/19Alexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/19Roche to Pay $2.4 Billion for Full Control of Foundation Medicine -- 2nd Upda..
DJ
06/19Roche pays $2.4 billion for rest of cancer expert Foundation Medicine
RE
More sector news : Pharmaceuticals - NEC
Latest Tweets
05/16$GALE Life Sciences Group Inc SELLAS Life Sciences Group Inc (GALE) - Pharma.. 
05/04Richard Chin Sells 20,000 Shares of Kindred Biosciences $KIN Stock  
04/20$SLS - Galena Biopharma #SLS Given Daily Media Impact Rating of 0.23  
04/13SELLAS Life Sciences Group Inc GALE Pharmaceuticals Healthcare Deals and Alli.. 
02/13 SELLAS Life Sciences Group Inc GALE Medical Equipment Deals and Alliances Pr.. 
More tweets
Qtime:92
News from SeekingAlpha
2016Galena Biopharma's (GALE) CEO Mark Schwartz on Q3 2016 Results - Earnings Cal.. 
2016Galena Biopharma beats by $0.02 
2016Notable earnings after Wednesday?s close 
2016RXI PHARMACEUTICALS : Moving On Promising Scar Treatment 
2016Best And Worst Performing Stocks Of 2016 
Technical analysis trends GALENA BIOPHARMA INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 12,0 $
Spread / Average Target 145%
EPS Revisions
Managers
NameTitle
Angelos M. Stergiou President, Chief Executive Officer & Director
Jane Wasman Independent Chairman
Gene C. Mack Chief Financial Officer & Treasurer
Nicholas J. Sarlis Chief Medical Officer & Executive Vice President
John W. Varian Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GALENA BIOPHARMA INC33
JOHNSON & JOHNSON-12.25%328 858
PFIZER0.39%212 690
NOVARTIS-8.25%193 330
ROCHE HOLDING LTD.-14.81%184 168
MERCK AND COMPANY8.39%166 880